Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 754 across all filing types
Latest filing 2023-08-25 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled '2023 年半年度报告摘要' which translates to '2023 Semi-Annual Report Summary'. It contains detailed financial data such as total assets, net profit, revenue, and shareholder information for the half-year period. The document explicitly states it is a half-year report summary and references the full semi-annual report for more details. The presence of substantive financial data and analysis for a period shorter than a full fiscal year aligns with the definition of an Interim / Quarterly Report (IR). The document length is 3037 characters, which is sufficient to contain actual financial data, not just an announcement or certification. Therefore, the document is classified as an Interim / Quarterly Report (IR). H1 2023
2023-08-25 Chinese
独立董事关于第二届董事会第九次会议相关议案的独立意见
Board/Management Information Classification · 90% confidence The document is an independent opinion from the independent directors regarding the company's 2023 half-year fundraising funds storage and usage report. It references compliance with regulatory guidelines and confirms proper use of funds. The document is short (1063 characters) and primarily provides an opinion on a specific agenda item from a board meeting, without containing detailed financial statements or comprehensive financial data. It is not a full interim or annual report, nor an earnings release. It is also not a certification or a simple announcement of a report publication. The content aligns with a Board/Management Information type, as it relates to board meeting agenda and opinions on company matters.
2023-08-25 Chinese
2023年半年度募集资金存放及实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management and actual use of funds raised by the company during the half-year period ending June 30, 2023. It references regulatory guidelines related to the management and use of raised funds, provides detailed financial figures on the raised capital, its allocation, usage, and balance, and includes information on compliance with relevant laws and regulations. The document is titled as a "专项报告" (special report) on the half-year fundraising funds deposit and actual usage situation. This type of report is specific to the use and management of capital raised by the company, which aligns with the category of Capital/Financing Update (CAP). The document is not an announcement of a report publication, nor is it a full annual or interim financial report. It is a substantive report focused on fundraising capital management and usage, consistent with the CAP category.
2023-08-25 Chinese
关于召开2023年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of a 2023 half-year performance explanation meeting (业绩说明会) for investors, to be held on September 1, 2023. It mentions that the company will release its 2023 half-year report on August 26, 2023, and the meeting is intended to discuss the half-year operating results and financial indicators interactively with investors. The document does not contain actual financial statements or detailed financial data but rather provides logistical details about the meeting, how investors can participate, and how to submit questions. The document length is short (1384 characters), and it serves as a notice for an upcoming investor presentation rather than the presentation or report itself. Therefore, it fits best under the category of Investor Presentation (IP) as it is about a detailed presentation for investors focusing on financials, strategy, and market position, even though the actual presentation will occur later. It is not a full report (like IR or 10-K), nor is it a simple announcement of report publication (RPA) because it is about the meeting to explain the report, which is typical for IP filings.
2023-08-24 Chinese
北京市嘉源律师事务所关于科兴生物制药股份有限公司2023年第二次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, attendance, and voting results of a company's 2023 second extraordinary general meeting (临时股东大会). It details the legal compliance of the meeting's call, attendance, and voting process, and confirms the validity of the resolutions passed. The document does not contain financial statements or management discussion but focuses on legal compliance and meeting procedures. It is not an announcement of a report but a legal opinion related to a shareholders' meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official voting results and meeting procedural compliance.
2023-08-10 Chinese
2023年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the company's 2023 second extraordinary general meeting of shareholders, including voting results on various proposals related to a specific share issuance and other corporate matters. It includes attendance details, voting percentages, and legal witness statements confirming the validity of the meeting and votes. There is no financial data or report content, but rather the official voting results and meeting procedural information. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). The document length is sufficient and contains substantive voting details, not just a brief notice or report publication announcement.
2023-08-10 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.